Get the Stockscreener App
10.38
3.80%
-0.41
Pre-market:
9.87
-0.51
-4.91%
Evolus Inc stock is traded at $10.38, with a volume of 657.74K.
It is down -3.80% in the last 24 hours and down -20.34% over the past month.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
See More
Previous Close:
$10.79
Open:
$10.64
24h Volume:
657.74K
Relative Volume:
0.78
Market Cap:
$653.04M
Revenue:
$202.09M
Net Income/Loss:
$-61.69M
P/E Ratio:
-9.6111
EPS:
-1.08
Net Cash Flow:
$-35.64M
1W Performance:
+1.07%
1M Performance:
-20.34%
6M Performance:
-36.08%
1Y Performance:
-9.97%
1-Day Range:
$10.20
$10.70
1-Week Range:
$9.82
$10.97
52-Week Range:
$8.67
$17.82
Evolus Inc Stock (EOLS) Company Profile
Name
Evolus Inc
Sector
Phone
(949) 284-4555
Address
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Compare EOLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
10.38 | 653.04M | 202.09M | -61.69M | -35.64M | -1.08 |
|
ZTS
Zoetis Inc
|
146.85 | 67.28B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.19 | 45.61B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.93 | 45.01B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
13.31 | 15.25B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
284.25 | 12.77B | 2.76B | 1.11B | 898.10M | 22.77 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-25 | Initiated | BTIG Research | Buy |
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-23-22 | Initiated | Needham | Buy |
| May-12-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-20-22 | Upgrade | Truist | Hold → Buy |
| May-06-21 | Upgrade | Mizuho | Neutral → Buy |
| Apr-08-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-21 | Downgrade | Truist | Buy → Hold |
| Jul-07-20 | Downgrade | Mizuho | Buy → Neutral |
| Feb-06-20 | Resumed | Mizuho | Buy |
| Nov-26-19 | Initiated | SVB Leerink | Outperform |
| Sep-05-19 | Resumed | Mizuho | Buy |
| Jun-28-19 | Initiated | Wells Fargo | Market Perform |
| Jun-11-19 | Initiated | Barclays | Underweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Jan-29-19 | Initiated | Stifel | Buy |
View All
Evolus Inc Stock (EOLS) Latest News
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | EOLS Stock News - GuruFocus
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Evolus Strengthens Talent Strategy: 30,579 RSUs Granted to Key New Hires with 2025 Vesting - Stock Titan
Midday Stock Roundup: US Markets Closed for Good Friday - Orange County Business Journal
Evolus announces commercial launch of Evolysse - MSN
BTIG Initiates Coverage of Evolus (EOLS) with Buy Recommendation - Nasdaq
BTIG Initiates Evolus at Buy With $21 Price Target - marketscreener.com
Evolus initiated with a Buy at BTIG - TipRanks
BTIG Initiates Coverage on Evolus (EOLS) with Optimistic Outlook | EOLS Stock News - GuruFocus
Evolus Launches "Drop The F Word" To Redefine Aesthetic Injectables With Evolysse - Nasdaq
Evolus Announces Commercial Launch of Evolysse™ | EOLS Stock New - GuruFocus
Game-Changing Dermal Filler Outperforms Restylane in Clinical Trials: Evolus Expands Portfolio - Stock Titan
Evolus Launches “Drop the F Word” Campaign in Advance of the Com - GuruFocus
Game-Changing Cold-X Technology: Evolus Revolutionizes Injectable Aesthetics with Natural Results - Stock Titan
H.C. Wainwright maintains Buy on Evolus stock with $27 target - Investing.com
H.C. Wainwright maintains Buy on Evolus stock with $27 target By Investing.com - Investing.com Canada
Evolus stock hits 52-week low at $9.22 amid market challenges - Investing.com Canada
Evolus stock hits 52-week low at $9.22 amid market challenges By Investing.com - Investing.com South Africa
Midday Stock Roundup: Evolus, ICU Medical down - Orange County Business Journal
Breaking Down Evolus: 8 Analysts Share Their Views - Benzinga
Investors Give Evolus, Inc. (NASDAQ:EOLS) Shares A 31% Hiding - simplywall.st
Evolus at Needham Conference: Strategic Launch of Evolisse By Investing.com - Investing.com Canada
Evolus at Needham Conference: Strategic Launch of Evolisse - Investing.com
Sandra Beaver: Evolus on Track to Hit $700M Revenue - Orange County Business Journal
Recent 11% pullback isn't enough to hurt long-term Evolus (NASDAQ:EOLS) shareholders, they're still up 170% over 5 years - simplywall.st
Evolus, Inc.: Navigating Financial Challenges Amidst Ongoing Losses and Market Uncertainty - MSN
Evolus CEO David Moatazedi sells $77,512 in stock By Investing.com - Investing.com India
Evolus CEO David Moatazedi sells $77,512 in stock - Investing.com Australia
Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference - BioSpace
Evolus Inc (EOLS) Shares Down 4.54% on Mar 25 - GuruFocus
Evolus Leadership Reveals Growth Strategy at Major Healthcare Conference - Stock Titan
Investing in Evolus (NASDAQ:EOLS) five years ago would have delivered you a 216% gain - Yahoo Home
Evolus reports inducement grants under Nasdaq listing rule 5635(C)(4) -March 21, 2025 at 04:17 pm EDT - MarketScreener
Evolus director David Moatazedi sells $1.37 million in stock By Investing.com - Investing.com Australia
Evolus Growth Continues: 14 New Employees Join as Company Strengthens Talent Pool - Stock Titan
Evolus to Participate in Canaccord Genuity’s 43rd Annual Growth Conference - Business Wire
Evolus executive Avelar Rui sells $369,867 in stock By Investing.com - Investing.com South Africa
Evolus CFO Sandra Beaver sells $119,242 in company stock By Investing.com - Investing.com South Africa
Evolus chief marketing officer sells $60,124 in common stock By Investing.com - Investing.com South Africa
Evolus CFO Sandra Beaver sells $119,242 in company stock - Investing.com
Evolus director David Moatazedi sells $1.37 million in stock - Investing.com India
Evolus chief marketing officer sells $60,124 in common stock - Investing.com
When the Price of (EOLS) Talks, People Listen - news.stocktradersdaily.com
Trade Alert: Independent Director Of Evolus Karah Parschauer Has Sold Stock - Simply Wall St
Evolus director Parschauer sells $167,465 in common stock By Investing.com - Investing.com India
Demonstrates Effects Lasting 26 Weeks in Phase II Data Presented at 2023 ASDS Annual Meeting - Business Wire
Evolus Inc Stock (EOLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.47%
0.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):